Quest Diagnostics Incorporated
DGX Healthcare Diagnostics & Research
Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 14.7%, free cash flow grew 5.28% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow DGX
Quest Diagnostics Incorporated (DGX) Revenue
Quest Diagnostics Incorporated's revenue for fiscal 2025 was $11.0B, up 11.8% from $9.9B in fiscal 2024. Over the twelve months to 30 June 2026 it was $11.6B. Over the past ten years it has ranged from $7.2B (fiscal 2016) to $11.0B (fiscal 2025) — the current reading is the highest in ten years. Quest Diagnostics Incorporated ranks 5th of 50 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $11.0B | 11.78% |
| FY2024 | $9.9B | 6.70% |
| FY2023 | $9.3B | (6.38%) |
| FY2022 | $9.9B | (8.39%) |
| FY2021 | $10.8B | 14.32% |
| FY2020 | $9.4B | 22.15% |
| FY2019 | $7.7B | 2.59% |
| FY2018 | $7.5B | 1.74% |
| FY2017 | $7.4B | 2.61% |
| FY2016 | $7.2B | (3.72%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $3.0B | 5.11% |
| Mar 2026 | $2.9B | 3.17% |
| Dec 2025 | $2.8B | (0.36%) |
| Sep 2025 | $2.8B | 1.99% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| LH Labcorp Holdings Inc. compare | $14.3B |
| DGX Quest Diagnostics Incorporated | $11.6B |
| WAT Waters Corporation compare | $4.6B |
| IDXX IDEXX Laboratories, Inc. compare | $4.6B |
| ILMN Illumina, Inc. compare | $4.5B |
| MTD Mettler-Toledo International, Inc. compare | $4.1B |
| RVTY Revvity Inc. compare | $2.9B |
| MEDP Medpace Holdings, Inc. compare | $2.8B |
| GH Guardant Health, Inc. compare | $1.2B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on DGX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement